The large class of CNS-depressant medications—the benzodiazepines—have been extensively used for over 50 years, anxiety disorders being one of the main indications. A substantial proportion (perhaps up to 20–30 %) of long-term users becomes physically dependent on them. Problems with their use became manifest, and dependence, withdrawal difficulties and abuse were documented by the 1980s. Many such users experience physical and psychological withdrawal symptoms on attempted cessation and may develop clinically troublesome syndromes even during slow tapering. Few studies have been conducted to establish the optimal withdrawal schedules. The usual management comprises slow withdrawal over weeks or months together with psychotherapy of various modalities. Pharmacological aids include antidepressants such as the SSRIs especially if depressive symptoms supervene. Other pharmacological agents such as the benzodiazepine antagonist, flumazenil, and the hormonal agent, melatonin, remain largely experimental. The purpose of this review is to analyse the evidence for the efficacy of the usual withdrawal regimes and the newer agents. It is concluded that little evidence exists outside the usual principles of drug withdrawal but there are some promising leads.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
D’Hulst C, Atack J, Kooy R. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov Today. 2009;14(17–18):866–75.
Lader M. Benzodiazepines revisited-will we ever learn? Addiction. 2011;106(12):2086–109.
O’Brien C. Benzodiazepine use, abuse and dependence. J Clin Psychiatry. 2005;66:28–33.
Donoghue J, Lader M. Usage of benzodiazepines: a review. Int J Psychiatry Clin Pract. 2010;14(2):78–87.
Locke A, Kirst N, Shultz C. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2015;91:617–24.
Cloos J, Ferreira V. Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry. 2009;22(1):90–5.
Baldwin D, Aitchison K, Bateson A, Curran H, Davies S, Leonard B, et al. Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol. 2013;27(11):967–71. A reconsideration of the risk/benefit of benzodiazepines.
Rcpsych.ac.uk. Benzodiazepines [Internet]. 2015 [cited 19 June 2015]. Available from: http://www.rcpsych.ac.uk/healthadvice/treatmentswellbeing/benzodiazepines.aspx.
Mehdi T. Benzodiazepines revisited. Br J Med Pract Manage. 2012;5(1):a501.
Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249–55.
Petursson H, Lader M. Dependence on tranquillizers. Oxford: Oxford University Press; 1984.
Tvete I, Bjorner T, Aursnes I, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open. 2013;3(10):e003296.
Vinkers C, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharm Sci. 2012;2012:1–19.
Manthey L, Lohbeck M, Giltay E, van Veena T, Zitman F, Penninx B. Correlates of benzodiazepine dependence in the Netherlands study of depression and anxiety. Addiction. 2012;107(12):2173–82. Presents predictive data on dependence liability.
Cuevas C, Sanz E, Fuente J, Padilla J, Berenguer J. The severity of dependence scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction. 2000;95(2):245–50.
Schweizer E, Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand. 1998;98(s393):95–101.
Higgitt A, Fonagy P, Toone B, Shine P. The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria? Acta Psychiatr Scand. 1990;82(2):165–8.
Hallstrom C, Lader M. Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry. 1981;16:235–44.
Lader M. Long-term anxiolytic therapy: the issue of drug withdrawal. J Clin Psychiatry. 1987;1(48 Suppl):12–6.
Vikander B, Koechling U, Borg S, Tönne U, Hiltunen A. Benzodiazepine tapering: a prospective study. Nord J Psychiatry. 2010;64(4):273–82.
Russell J, Lader M. Guidelines for the prevention and treatment of benzodiazepine dependence. London: The Mental Health Foundation; 1994.
Mcgregor C, Machin A, White J. In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug Alcohol Rev. 2003;22(2):175–80.
Kan C, Breteler M, Zitman F. High prevalence of benzodiazepine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand. 1997;96(2):85–93.
de Gier N, Gorgels W, Lucassen P, Oude Voshaar R, Mulder J, Zitman F. Discontinuation of long-term benzodiazepine use: 10-year follow-up. Fam Pract. 2010;28(3):253–9.
Lingford-Hughes A, Welch S, Peters L, Nutt D. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol. 2012;26(7):899–952. An authoritative review on the features and management of various types of addiction.
Ashton C. Benzodiazepines: how they work & how to withdraw. Newcastle: University of Newcastle; 2001.
Higgitt A, Lader M, Fonagy P. Clinical management of benzodiazepine dependence. BMJ. 1985;291(6503):1202.
Voshaar R. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189(3):213–20.
Denis D, Fatseas M, Lavie E, Auriscombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2007. CD005194.
Murphy S, Tyrer P. A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry. 1991;158(4):511–6.
Voshaar R, Gorgels W, Mol A, Van Balkom A, Mulder J, Van De Lisdonk E, et al. Long-term outcome of two forms of randomised benzodiazepine discontinuation. Br J Psychiatry. 2006;188(2):188–9.
Podhorna J. The experimental pharmacotherapy of benzodiazepine withdrawal. Curr Pharm Des. 2002;8(1):23–43.
Sullivan M, Toshima M, Lynn P, Roy-Byrne P. Phenobarbital versus clonazepam for sedative-hypnotic taper in chronic pain patients: a pilot study. Ann Clin Psychiatry. 1993;5(2):123–8.
Kawasaki S, Jacapraro J, Rastegar D. Safety and effectiveness of a fixed-dose phenobarbital protocol for inpatient benzodiazepine detoxification. J Subst Abus Treat. 2012;43(3):331–4.
Schweizer E. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Arch Gen Psychiatry. 1991;48(5):448.
Efficacy of drug treatments for Generalised Anxiety Disorder: systematic review and meta-analysis. BMJ. 2011;342(mar16 2):d1718-d1718.
Baldwin D, Anderson I, Nutt D, Allgulander C, Bandelow B, den Boer J, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403–39. An authoritative survey of the treatments available to treat various anxiety disorders.
Baldwin D, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007;3(2):185–91.
Hadley S, Mandel F, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2011;26(4):461–70.
Crockford D, White W, Campbell B. Gabapentin use in benzodiazepine dependence and detoxification. Can J Psychiatr. 2001;46:287.
Chessick C, Allen M, Thase M. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2015;3, CD006115.
Ashton C, Rawlins M, Tyrer S. A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users. Br J Psychiatry. 1990;157(2):232–8.
Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev. 2010;12. CD006815.
Gao K, Sheehan D, Calabrese J. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother. 2009;9(8):1147–58.
Vulink N, Figee M, Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol. 2011;21(6):429–49.
Srinivasan V, Brzezinski A, Pandi-Perumal S, Spence D, Cardinali D, Brown G. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(4):913–23.
Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin. Arch Intern Med. 1999;159(20):2456.
Peles E, Hetzroni T, Bar-Hamburger R, Adelson M, Schreiber S. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. Addiction. 2007;102(12):1947–53.
Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2012;69(4):1–10.
Rickels K, DeMartinis N, Rynn M, Mandos L. Pharmacologic strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19:12S–6S.
Tyrer P, Ferguson B, Hallstrom C, Michie M, Tyrer S, Cooper S, et al. A controlled trial of dothiepin and placebo in treating benzodiazepine withdrawal symptoms. Br J Psychiatry. 1996;168(4):457–61.
Zitman FG, Couveé JE. Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off. Report on behalf of the Dutch Chronic Benzodiazepine Working Group. Br J Psychiatry. 2001;178(4):317–24.
Nakao M, Takeuchi T, Nomura K, Teramoto T, Yano E. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry Clin Neurosci. 2006;60(5):605–10.
Spiegel D. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol. 1999;19:17S–22S.
Voshaar R, Gorgels W, Mol A, Van Balkom A, Van de Lisdonk E, Breteler M, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry. 2003;182(6):498–504.
Gosselin P, Ladouceur R, Morin C, Dugas M, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74(5):908–19.
Baillargeon L, Landreville P, Verreault R, Beauchemin J, Gregoire J, Morin C. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering; a randomized trial. Can Med Assoc J. 2003;169:1015–20.
Ten Wolde G, Dijkstra A, van Empelen P, van den Hout W, Knuistingh Neven A, Zitman F. Long-term effectiveness of computer-generated tailored patient education on benzodiazepines: a randomized controlled trial. Addiction. 2008;103(4):662–70.
Parr J, Kavanagh D, Cahill L, Mitchell G, Young R. Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2009;104(1):13–24.
Smith A, Tett S. Improving the use of benzodiazepines—is it possible? A non-systematic review of interventions tried in the last 20 years. BMC Health Serv Res. 2010;10(1):321.
Gould R, Coulson M, Patel N, Highton-Williamson E, Howard R. Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. Br J Psychiatry. 2014;204(2):98–107.
Hood S, Norman A, Hince D, Melichar J, Hulse G. Benzodiazepine dependence and its treatment with low dose flumazenil. Br J Clin Pharmacol. 2014;77(2):285–94.
Gerra G, Giucasto G, Zaimovic A, Fertonani G, Chittolini B, Avanzini P, et al. Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal. Int Clin Psychopharmacol. 1996;11(2):81–8.
Griffiths R, Evans S, Guarino J. Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal. J Pharmacol Exp Ther. 1993;265:1163–74.
Mintzer M, Stoller K, Griffiths R. A controlled study of flumazenil-precipitated withdrawal in chronic low-dose benzodiazepine users. Psychopharmacology. 1999;147(2):200–9.
Lader M, Morton S. A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. J Psychopharmacol. 1992;6(3):357–63.
Saxon L, Hjemdahl P, Hiltunen A, Borg S. Effects of flumazenil in the treatment of benzodiazepine withdrawal—a double-blind pilot study. Psychopharmacology. 1997;131(2):153–60.
Gerra G, Zaimovic A, Giusti F, Moi G, Brewer C. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study. Addict Biol. 2002;7(4):385–95.
Hood S, O’Neil G, Hulse G. The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. J Psychopharmacol. 2009;23(4):401–9.
Quaglio G, Pattaro C, Gerra G, Mathewson S, Verbanck P, Des Jarlais D, et al. High dose benzodiazepine dependence: description of 29 patients treated with flumazenil infusion and stabilised with clonazepam. Psychiatry Res. 2012;198(3):457–62.
Hulse G, O’Neil G, Morris N, Bennett K, Norman A, Hood S. Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series. J Psychopharmacol. 2012;27(2):222–7.
Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19.
Parr J, Kavanagh D, Young R, Mitchell G. Acceptability of cognitive-behaviour therapy via the internet for cessation of benzodiazepine use. Drug Alcohol Rev. 2011;30(3):306–14.
Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K. Treatment of out-patients with complicated benzodiazepine dependence: comparison of two approaches. Addiction. 2002;97(7):851–9.
Lugoboni F, Quaglio G. Exploring the dark side of the moon: the treatment of benzodiazepine tolerance. Br J Clin Pharmacol. 2014;77(2):239–41. An expert account of the management of benzodiazepine dependence and withdrawal.
Barker M. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19(3):437–54.
Conflict of Interest
Malcolm Lader and Andri Kyriacou declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on Anxiety Disorders
About this article
Cite this article
Lader, M., Kyriacou, A. Withdrawing Benzodiazepines in Patients With Anxiety Disorders. Curr Psychiatry Rep 18, 8 (2016). https://doi.org/10.1007/s11920-015-0642-5
- Clinical risks